Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 40

Sort by

Sort Order Select

Journal Articles

Abstract GS02-05: Overview of Axillary Treatment in Early Breast Cancer: patient-level meta-analysis of long-term outcomes among 20,273 women in 29 randomised trials

Cancer Res (2024) 84 (9_Supplement): GS02-05.

https://doi.org/10.1158/1538-7445.SABCS23-GS02-05

Published: 02 May 2024

View article titled, Abstract GS02-05: Overview of Axillary Treatment in Early Breast Cancer: patient-level meta-analysis of long-term outcomes among 20,273 women in 29 randomised trials

Journal Articles

Abstract PO2-07-06: Multimodal learning predictor of HER2-positive breast cancer therapy response in the randomized PREDIX HER2 trial

Kang Wang, Yajing Zhu, Ioannis Zerdes, Emmanouil Sifakis, Georgios Manikis, Dimitrios Salgkamis, Nikolaos Tsiknakis, Luuk Harbers, Nicola Crosetto, Jonas Bergh, Alexios Matikas, Thomas Hatschek, Theodoros Foukakis

Cancer Res (2024) 84 (9_Supplement): PO2-07-06.

https://doi.org/10.1158/1538-7445.SABCS23-PO2-07-06

Published: 02 May 2024

View article titled, Abstract PO2-07-06: Multimodal learning predictor of HER2-positive breast cancer therapy response in the randomized PREDIX HER2 trial

Journal Articles

Abstract P2-21-02: Longitudinal tumor-immune microenvironment changes in patients with clinical luminal A early breast cancer treated with neoadjuvant palbociclib and endocrine therapy: results from the Swedish randomized PREDIX Luminal A trial

Ioannis Zerdes, Dimitrios Salgkamis, Alexios Matikas, Lars Selander, Kang Wang, Evangelos Tzoras, Emmanouil Sifakis, Susanne Agartz, Xinsong Chen, Mats Hellström, Johan Hartman, Jonas Bergh, Theodoros Foukakis, Thomas Hatschek

Cancer Res (2023) 83 (5_Supplement): P2-21-02.

https://doi.org/10.1158/1538-7445.SABCS22-P2-21-02

Published: 01 March 2023

View article titled, Abstract P2-21-02: Longitudinal tumor-immune microenvironment changes in patients with clinical luminal A early breast cancer treated with neoadjuvant palbociclib and endocrine therapy: results from the Swedish randomized PREDIX Luminal A trial

Journal Articles

Abstract P5-02-20: Correlative and longitudinal transcriptomic profiling predicts patient outcomes and the efficacy of neoadjuvant HER2-targeted treatments in the randomized PREDIX HER2 trial

Cancer Res (2023) 83 (5_Supplement): P5-02-20.

https://doi.org/10.1158/1538-7445.SABCS22-P5-02-20

Published: 01 March 2023

View article titled, Abstract P5-02-20: Correlative and longitudinal transcriptomic profiling predicts patient outcomes and the efficacy of neoadjuvant HER2-targeted treatments in the randomized PREDIX HER2 trial

Journal Articles

Abstract PD14-08: Effectiveness of aromatase inhibitors versus tamoxifen in lobular compared to ductal carcinoma: Individual patient data meta-analysis of 9328 women with central histopathology, and 7654 women with e-Cadherin status

Cancer Res (2022) 82 (4_Supplement): PD14-08.

https://doi.org/10.1158/1538-7445.SABCS21-PD14-08

Published: 15 February 2022

View article titled, Abstract PD14-08: Effectiveness of aromatase inhibitors versus tamoxifen in lobular compared to ductal carcinoma: Individual patient data meta-analysis of 9328 women with central histopathology, and 7654 women with e-Cadherin status

Journal Articles

Abstract GS2-06: Taxane with anthracycline versus taxane without anthracycline: An individual patient-level meta-analysis of 16,500 women with early-stage breast cancer in 13 randomised trials

Jeremy Braybrooke, Rosie Bradley, Richard Gray, Robert Hills, Zulian Liu, Hongchao Pan, Richard Peto, Joanne Blum, Xiaosong Chen, Bent Ejlertsen, Wolfgang Janni, Ulrike Nitz, Dennis Slamon, Masakazu Toi, Toru Watanabe, Sandra Swain, Jonas Bergh, on behalf of the Early Breast Cancer Trialists Collaborative Group

Cancer Res (2022) 82 (4_Supplement): GS2-06.

https://doi.org/10.1158/1538-7445.SABCS21-GS2-06

Published: 15 February 2022

View article titled, Abstract GS2-06: Taxane with anthracycline versus taxane without anthracycline: An individual patient-level meta-analysis of 16,500 women with early-stage breast cancer in 13 randomised trials

Journal Articles

Abstract GS2-04: Aromatase inhibitors versus tamoxifen in pre-menopausal women with estrogen receptor positive early stage breast cancer treated with ovarian suppression: A patient level meta-analysis of 7,030 women in four randomised trials

Rosie Bradley, Jeremy Braybrooke, Richard Gray, Robert K Hills, Zulian Lui, Hongchao Pan, Richard Peto, Jonas Bergh, Sandra M Swain, Prudence Francis, Michael Gnant, Francesco Perrone, Meredith M Regan

Cancer Res (2022) 82 (4_Supplement): GS2-04.

https://doi.org/10.1158/1538-7445.SABCS21-GS2-04

Published: 15 February 2022

View article titled, Abstract GS2-04: Aromatase inhibitors versus tamoxifen in pre-menopausal women with estrogen receptor positive early stage breast cancer treated with ovarian suppression: A patient level meta-analysis of 7,030 women in four randomised trials

Journal Articles

Abstract GS1-01: KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses

Cancer Res (2022) 82 (4_Supplement): GS1-01.

https://doi.org/10.1158/1538-7445.SABCS21-GS1-01

Published: 15 February 2022

View article titled, Abstract GS1-01: KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses

Journal Articles

Abstract PS18-27: Integrated immuno-genomic analyses in early breast cancer: Results from the Scandinavian breast group 2004-1 (SBG-2004-1) randomized phase II trial

Ioannis Zerdes, Michele Simonetti, Alexios Matikas, Luuk Harbers, Ning Zhang, Dimitrios Salgkamis, Susanne Agartz, Markella Zacharouli, Pablo Moreno-Ruiz, Johan Hartman, Artur Mezheyeuski, Jonas Bergh, Nicola Crosetto, Theodoros Foukakis

Cancer Res (2021) 81 (4_Supplement): PS18-27.

https://doi.org/10.1158/1538-7445.SABCS20-PS18-27

Published: 15 February 2021

View article titled, Abstract PS18-27: Integrated immuno-genomic analyses in early breast cancer: Results from the Scandinavian breast group 2004-1 (SBG-2004-1) randomized phase II trial

Journal Articles

Abstract P3-08-07: Expression of the novel tumor suppressor gene SAMHD1 correlates with favourable clinical outcome in basal-like (BL) early breast cancer

Maria Kouvaraki, Emmanuil G Sifakis, Ioannis Zerdes, Nikolas Herold, Jonas Bergh, George Z. Rassidakis, Theodoros Foukakis

Cancer Res (2020) 80 (4_Supplement): P3-08-07.

https://doi.org/10.1158/1538-7445.SABCS19-P3-08-07

Published: 15 February 2020

View article titled, Abstract P3-08-07: Expression of the novel tumor suppressor gene SAMHD1 correlates with favourable clinical outcome in basal-like (BL) early breast cancer

Journal Articles

Abstract P3-08-22: The mutational landscape of cancer driver genes in matched primary ductal carcinoma in situ and recurrent ductal carcinoma in situ or recurrent invasive cancers

Jane Bayani, Quang M Trinh, Mary Anne Quintayo, Cheryl Crozier, Ilinca Lungu, Dan Dion, Joema Felipe-Lima, Giancarlo Pruneri, Jonas Bergh, Fredrik Warnberg, Giuseppe Viale, Lincoln D Stein, John MS Bartlett

Cancer Res (2020) 80 (4_Supplement): P3-08-22.

https://doi.org/10.1158/1538-7445.SABCS19-P3-08-22

Published: 15 February 2020

View article titled, Abstract P3-08-22: The mutational landscape of cancer driver genes in matched primary ductal carcinoma <em>in situ</em> and recurrent ductal carcinoma <em>in situ</em> or recurrent invasive cancers

Journal Articles

Abstract P6-10-24: High stromal platelet derived growth factor receptor beta predicts absence of benefit of radiotherapy after breast conserving surgery in breast ductal carcinoma in situ within the SweDCIS randomized trial

Carina Strell, Dick Folkvaljon, Erik Holmberg, Per Karlsson, Jonas Bergh, Troy Bremer, Lars A. Akslen, Fredrik Wärnberg, Arne Östman

Cancer Res (2020) 80 (4_Supplement): P6-10-24.

https://doi.org/10.1158/1538-7445.SABCS19-P6-10-24

Published: 15 February 2020

View article titled, Abstract P6-10-24: High stromal platelet derived growth factor receptor beta predicts absence of benefit of radiotherapy after breast conserving surgery in breast ductal carcinoma in situ within the SweDCIS randomized trial

Journal Articles

Abstract GS2-04: Improvements in long-term outcome for women with estrogen receptor positive (ER+) early stage breast cancer treated with 5 years of endocrine therapy: Analyses of 82,598 women in the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) database

Hongchao Pan, Jeremy Braybrooke, Richard Gray, Richard Peto, Rosie Bradley, Robert Hills, Jonas Bergh, Sandra M Swain, Mitchell Dowsett, Daniel F Hayes, Richard D Gelber, for the EBCTCG

Cancer Res (2020) 80 (4_Supplement): GS2-04.

https://doi.org/10.1158/1538-7445.SABCS19-GS2-04

Published: 15 February 2020

View article titled, Abstract GS2-04: Improvements in long-term outcome for women with estrogen receptor positive (ER+) early stage breast cancer treated with 5 years of endocrine therapy: Analyses of 82,598 women in the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) database

Journal Articles

Abstract 5655: Biophysics in the cell—CETSA to study drug binding and cellular processes in cancer therapy

Ying Yu Liang, Anderson Ramos, Henriette Laursen, Olga Surova, Johan Lengqvist, Sara Lööf, Anette Langebäck, Smaranda Bacanu, Jonas Bergh, Pär Nordlund

Cancer Res (2018) 78 (13_Supplement): 5655.

https://doi.org/10.1158/1538-7445.AM2018-5655

Published: 01 July 2018

View article titled, Abstract 5655: Biophysics in the cell—CETSA to study drug binding and cellular processes in cancer therapy

Journal Articles

Abstract 3933: CETSA as a diagnostic tool to guide personalized breast cancer therapy

Anette Öberg, Henriette Laursen, Sylvia Packham, Daniel Martinez Molina, Takahiro Seki, Yihai Cao, Johan Hartman, Jonas Bergh, Pär Nordlund, Sara Lööf.

Cancer Res (2016) 76 (14_Supplement): 3933.

https://doi.org/10.1158/1538-7445.AM2016-3933

Published: 15 July 2016

View article titled, Abstract 3933: CETSA as a diagnostic tool to guide personalized breast cancer therapy

Journal Articles

Guidance Molecule SEMA3A Restricts Tumor Growth by Differentially Regulating the Proliferation of Tumor-Associated Macrophages

Majken Wallerius, Tatjana Wallmann, Margarita Bartish, Jeanette Östling, Artur Mezheyeuski, Nicholas P. Tobin, Emma Nygren, Pradeepa Pangigadde, Paola Pellegrini, Mario Leonardo Squadrito, Fredrik Pontén, Johan Hartman, Jonas Bergh, Angelo De Milito, Michele De Palma, Arne Östman, John Andersson, Charlotte Rolny

Cancer Res (2016) 76 (11): 3166–3178.

https://doi.org/10.1158/0008-5472.CAN-15-2596

Published: 31 May 2016

View article titled, Guidance Molecule SEMA3A Restricts Tumor Growth by Differentially Regulating the Proliferation of Tumor-Associated Macrophages

Includes: Supplementary data

Journal Articles

Endothelial ALK1 Is a Therapeutic Target to Block Metastatic Dissemination of Breast Cancer

Sara I. Cunha, Matteo Bocci, John Lövrot, Nikolas Eleftheriou, Pernilla Roswall, Eugenia Cordero, Linda Lindström, Michael Bartoschek, B. Kristian Haller, R. Scott Pearsall, Aaron W. Mulivor, Ravindra Kumar, Christer Larsson, Jonas Bergh, Kristian Pietras

Cancer Res (2015) 75 (12): 2445–2456.

https://doi.org/10.1158/0008-5472.CAN-14-3706

Published: 14 June 2015

View article titled, Endothelial ALK1 Is a Therapeutic Target to Block Metastatic Dissemination of Breast Cancer

Includes: Supplementary data

Journal Articles

Abstract P3-11-14: Is pathologic complete response (pCR) a valid marker of outcome even in large breast cancer? Clinical results from a neoadjuvant trial using a combination of epirubicin, docetaxel and bevacizumab (PROMIX)

Thomas Hatschek, Judith Bjöhle, Elisabet Lidbrink, Tobias Lekberg, Niklas Loman, Anna von Wachenfeldt Väppling, Martin Söderberg, Zakaria Einbeigi, Lena Carlsson, Henrik Lindman, Irma Fredriksson, Jan Frisell, Lars Löfgren, Lisa Rydén, Mats Hellström, Mårten Fernö, Jonas Bergh

Cancer Res (2015) 75 (9_Supplement): P3-11-14.

https://doi.org/10.1158/1538-7445.SABCS14-P3-11-14

Published: 01 May 2015

View article titled, Abstract P3-11-14: Is pathologic complete response (pCR) a valid marker of outcome even in large breast cancer? Clinical results from a neoadjuvant trial using a combination of epirubicin, docetaxel and bevacizumab (PROMIX)

Journal Articles

Abstract P6-08-03: Transcriptional profiling of breast cancer metastases identifies liver metastasis-selective genes associated with adverse outcome in luminal A primary breast cancer

Siker Kimbung, Ida Johansson, Anna Danielsson, Srinivas Veerla, Suzanne Egyhazi, Jonas Bergh, Zakaria Einbeigi, Barbro Linderholm, Elisabet Lidbrink, Niklas Loman, Per Malmström, Martin Söderberg, Thomas M Walz, Mårten Fernö, Thomas Hatschek, Ingrid Hedenfalk, the TEX Study Group

Cancer Res (2015) 75 (9_Supplement): P6-08-03.

https://doi.org/10.1158/1538-7445.SABCS14-P6-08-03

Published: 01 May 2015

View article titled, Abstract P6-08-03: Transcriptional profiling of breast cancer metastases identifies liver metastasis-selective genes associated with adverse outcome in luminal A primary breast cancer

Journal Articles

Abstract P2-05-02: Preliminary translational results from PROMIX, a phase II trial of preoperative chemotherapy with the addition of bevacizumab in large operable and locally advanced HER2-negative breast cancer

Niklas Loman, Ida Johansson, Judith Bjöhle, Jan Frisell, Tobias Lekberg, Lisa Rydén, Anna von Wachenfeldt, Jonas Bergh, Thomas Hatschek, Ingrid Hedenfalk

Cancer Res (2015) 75 (9_Supplement): P2-05-02.

https://doi.org/10.1158/1538-7445.SABCS14-P2-05-02

Published: 01 May 2015

View article titled, Abstract P2-05-02: Preliminary translational results from PROMIX, a phase II trial of preoperative chemotherapy with the addition of bevacizumab in large operable and locally advanced HER2-negative breast cancer

NARROW

Abstract GS02-05: Overview of Axillary Treatment in Early Breast Cancer: patient-level meta-analysis of long-term outcomes among 20,273 women in 29 randomised trials

Abstract PO2-07-06: Multimodal learning predictor of HER2-positive breast cancer therapy response in the randomized PREDIX HER2 trial

Abstract P2-21-02: Longitudinal tumor-immune microenvironment changes in patients with clinical luminal A early breast cancer treated with neoadjuvant palbociclib and endocrine therapy: results from the Swedish randomized PREDIX Luminal A trial

Abstract P5-02-20: Correlative and longitudinal transcriptomic profiling predicts patient outcomes and the efficacy of neoadjuvant HER2-targeted treatments in the randomized PREDIX HER2 trial

Abstract PD14-08: Effectiveness of aromatase inhibitors versus tamoxifen in lobular compared to ductal carcinoma: Individual patient data meta-analysis of 9328 women with central histopathology, and 7654 women with e-Cadherin status

Abstract GS2-06: Taxane with anthracycline versus taxane without anthracycline: An individual patient-level meta-analysis of 16,500 women with early-stage breast cancer in 13 randomised trials

Abstract GS2-04: Aromatase inhibitors versus tamoxifen in pre-menopausal women with estrogen receptor positive early stage breast cancer treated with ovarian suppression: A patient level meta-analysis of 7,030 women in four randomised trials

Abstract GS1-01: KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses

Abstract PS18-27: Integrated immuno-genomic analyses in early breast cancer: Results from the Scandinavian breast group 2004-1 (SBG-2004-1) randomized phase II trial

Abstract P3-08-07: Expression of the novel tumor suppressor gene SAMHD1 correlates with favourable clinical outcome in basal-like (BL) early breast cancer

Abstract P3-08-22: The mutational landscape of cancer driver genes in matched primary ductal carcinoma in situ and recurrent ductal carcinoma in situ or recurrent invasive cancers

Abstract P6-10-24: High stromal platelet derived growth factor receptor beta predicts absence of benefit of radiotherapy after breast conserving surgery in breast ductal carcinoma in situ within the SweDCIS randomized trial

Abstract GS2-04: Improvements in long-term outcome for women with estrogen receptor positive (ER+) early stage breast cancer treated with 5 years of endocrine therapy: Analyses of 82,598 women in the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) database

Abstract 5655: Biophysics in the cell—CETSA to study drug binding and cellular processes in cancer therapy

Abstract 3933: CETSA as a diagnostic tool to guide personalized breast cancer therapy

Guidance Molecule SEMA3A Restricts Tumor Growth by Differentially Regulating the Proliferation of Tumor-Associated Macrophages

Endothelial ALK1 Is a Therapeutic Target to Block Metastatic Dissemination of Breast Cancer

Abstract P3-11-14: Is pathologic complete response (pCR) a valid marker of outcome even in large breast cancer? Clinical results from a neoadjuvant trial using a combination of epirubicin, docetaxel and bevacizumab (PROMIX)

Abstract P6-08-03: Transcriptional profiling of breast cancer metastases identifies liver metastasis-selective genes associated with adverse outcome in luminal A primary breast cancer

Abstract P2-05-02: Preliminary translational results from PROMIX, a phase II trial of preoperative chemotherapy with the addition of bevacizumab in large operable and locally advanced HER2-negative breast cancer

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only